One previous study reported that the frequency of IDH mutations did not differ between JAK2V617F mutant and JAK2V617F wild-type MPN patients (3.6% and 4.2%, respectively) [11]. This evidence concerns the gene IDH2 and myeloproliferative neoplasm.